HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Cullinan Therapeutics (NASDAQ:CGEM) and maintained a $28 price target.
June 03, 2024 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Cullinan Therapeutics and maintained a $28 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $28 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100